KR20080072084A - 뉴클레오티드 및 올리고뉴클레오티드 전구약물 - Google Patents
뉴클레오티드 및 올리고뉴클레오티드 전구약물 Download PDFInfo
- Publication number
- KR20080072084A KR20080072084A KR1020087015713A KR20087015713A KR20080072084A KR 20080072084 A KR20080072084 A KR 20080072084A KR 1020087015713 A KR1020087015713 A KR 1020087015713A KR 20087015713 A KR20087015713 A KR 20087015713A KR 20080072084 A KR20080072084 A KR 20080072084A
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- aryl
- hbv
- pronucleotide
- formula
- Prior art date
Links
- 0 CN(*)c1c2nc[n](C(C3)OC(COP(O[C@@](C(CO)OC4[n]5c6ncnc(N*)c6cc5)C4OC)(SCCCC**C(I)=O)=O)C3O*)c2ncn1 Chemical compound CN(*)c1c2nc[n](C(C3)OC(COP(O[C@@](C(CO)OC4[n]5c6ncnc(N*)c6cc5)C4OC)(SCCCC**C(I)=O)=O)C3O*)c2ncn1 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Abstract
Description
@ CsI/BF3.Et2O-16a와 R-OH의 반응에 의해 제조됨, # SOBr2/DCM을 지닌 ROH, §SOCl2/DMF/KI를 지닌 ROH;16b % 디-요오도부탄과 나트륨 니코티네이트의 반응에 의해 수득됨 * 상업적 소스로부터 수득됨 | * 관찰된 모 (5)로의 전환; @ 반감기는 에스테르의 가수분해 및 (5)가 발생하지 않는 추가 전환을 칭한다; % 프로뉴클레오티드는 혈청에서 24시간 후에도 변하지 않고 잔류함; § 화합물이 DMSO에 가용성이지 않은 것으로 측정되지 않음 |
Claims (13)
- 하기 화학식 (I)의 프로뉴클레오티드, 또는 이의 라세미체, 거울상이성질체, 부분입체이성질체, 기하 이성질체 또는 토오토머:상기 식에서,X는 부재이거나, O, NH, NR 또는 S이며;X1은 부재이거나, 0 또는 NH이며;A는 부재이거나, 아릴 또는 아르알킬이며;n은 0, 1, 2, 3, 4 또는 5이며;R은 알킬, 치환된 알킬, 시클로알킬, 아릴, 치환된 아릴, 아르알킬, 헤테로시클릭, O-알킬, 0-헤테로아릴 또는 스테로이달(steroidal)이며;R1, R2는 독립적으로 H, OH, 0-알킬, 알킬, 치환된 알킬, 시클로알킬, 아릴, 치환된 아릴, 아르알킬, 헤테로시클릭, 0-아릴, 0-헤테로아릴아릴 또는 헤테로시클릭이며;R3는 수소, 알킬, 치환된 알킬, C(O)-알킬, C(0)0-알킬, C(O)-아릴, C(0)0-아릴, C(O)NH-알킬 또는 C(O)NH-아릴로부터 선택되며;Y, Z는 독립적으로 0 및 S이며;B1, B2는 독립적으로 아데닌, 구아닌, 티민, 시토신, 우라실 또는 개질된 뉴클레오시드이며;m은 1 내지 40이다.
- 치료학적 유효량의 제 1항에 따른 화합물을 HBV 치료를 필요로 하는 피검체에 투여함을 포함하여, HBV 치료를 필요로 하는 피검체에서 HBV를 치료하는 방법.
- 치료학적 유효량의 제 1항에 따른 화합물을 다른 제제와 조합하여, HBV 치료를 필요로 하는 피검체에 투여함을 포함하여, HBV 치료를 필요로 하는 피검체에서 HBV를 치료하는 방법.
- 치료학적 유효량의 제 1항의 화합물을 단독으로 또는 다른 제제와 조합하여, HBV 치료를 필요로 하는 피검체에 투여함을 포함하여, HBV 치료를 필요로 하는 HBV의 내성 균주로 감염된 피검체에서 HBV를 치료하는 방법.
- 약제학적으로 허용되는 담체 또는 부형제와 조합하여 치료학적 유효량의 제 1항의 화합물을 포함하는 약제 조성물.
- 치료학적 유효량의 제 7항의 약제 조성물을 HBV 치료를 필요로 하는 피검체에 투여함을 포함하여, HBV 치료를 필요로 하는 피검체에서 HBV를 치료하는 방법.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75003605P | 2005-12-13 | 2005-12-13 | |
US60/750,036 | 2005-12-13 | ||
US80029406P | 2006-05-15 | 2006-05-15 | |
US60/800,294 | 2006-05-15 | ||
US11/637,520 | 2006-12-12 | ||
US11/637,520 US8076303B2 (en) | 2005-12-13 | 2006-12-12 | Nucleotide and oligonucleotide prodrugs |
PCT/US2006/047617 WO2007070598A2 (en) | 2005-12-13 | 2006-12-13 | Nucleotide and oligonucleotide prodrugs |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020117025810A Division KR101248873B1 (ko) | 2005-12-13 | 2006-12-13 | 뉴클레오티드 및 올리고뉴클레오티드 전구약물 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20080072084A true KR20080072084A (ko) | 2008-08-05 |
KR101123534B1 KR101123534B1 (ko) | 2012-03-13 |
Family
ID=38194676
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020117025810A KR101248873B1 (ko) | 2005-12-13 | 2006-12-13 | 뉴클레오티드 및 올리고뉴클레오티드 전구약물 |
KR1020087015713A KR101123534B1 (ko) | 2005-12-13 | 2006-12-13 | 뉴클레오티드 및 올리고뉴클레오티드 전구약물 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020117025810A KR101248873B1 (ko) | 2005-12-13 | 2006-12-13 | 뉴클레오티드 및 올리고뉴클레오티드 전구약물 |
Country Status (17)
Country | Link |
---|---|
US (6) | US8076303B2 (ko) |
EP (3) | EP1968612B1 (ko) |
JP (1) | JP5044854B2 (ko) |
KR (2) | KR101248873B1 (ko) |
CN (2) | CN102796155B (ko) |
CY (2) | CY1117576T1 (ko) |
DK (2) | DK3090748T3 (ko) |
ES (2) | ES2729657T3 (ko) |
HR (1) | HRP20160531T1 (ko) |
HU (2) | HUE029190T2 (ko) |
IN (1) | IN2015DN01786A (ko) |
LT (1) | LT3090748T (ko) |
PL (2) | PL3090748T3 (ko) |
PT (1) | PT3090748T (ko) |
RS (1) | RS54867B1 (ko) |
SI (2) | SI3090748T1 (ko) |
WO (1) | WO2007070598A2 (ko) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002219497B2 (en) * | 2001-01-16 | 2004-08-26 | Can-Fite Biopharma Ltd. | Use of an adenosine A3 receptor agonist for inhibition of viral replication |
US8076303B2 (en) * | 2005-12-13 | 2011-12-13 | Spring Bank Pharmaceuticals, Inc. | Nucleotide and oligonucleotide prodrugs |
WO2009146123A2 (en) | 2008-04-03 | 2009-12-03 | Spring Bank | Compositions and methods for treating viral infections |
EP3067359A1 (en) * | 2008-09-23 | 2016-09-14 | Scott G. Petersen | Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference |
CN102282155B (zh) | 2008-12-02 | 2017-06-09 | 日本波涛生命科学公司 | 磷原子修饰的核酸的合成方法 |
CA2747999A1 (en) * | 2008-12-23 | 2010-07-01 | Girindus America, Inc. | Sulfurizing reagents and their use for oligonucleotides synthesis |
AU2015255202B2 (en) * | 2009-07-06 | 2017-07-27 | Wave Life Sciences Ltd. | Novel nucleic acid prodrugs and methods of use thereof |
US9744183B2 (en) * | 2009-07-06 | 2017-08-29 | Wave Life Sciences Ltd. | Nucleic acid prodrugs and methods of use thereof |
CN101659612B (zh) * | 2009-09-24 | 2013-01-09 | 华润赛科药业有限责任公司 | 一种选择性酯化的方法 |
CN103298475A (zh) * | 2010-08-30 | 2013-09-11 | 斯普林银行医药公司 | 作为治疗剂的寡核苷酸类似物的设计 |
DK2620428T3 (da) | 2010-09-24 | 2019-07-01 | Wave Life Sciences Ltd | Asymmetrisk hjælpegruppe |
DK2734208T3 (en) | 2011-07-19 | 2017-06-19 | Wave Life Sciences Ltd | PROCEDURES FOR SYNTHESIS OF FUNCTIONALIZED NUCLEIC ACIDS |
KR101327026B1 (ko) | 2011-11-29 | 2013-11-13 | 현대자동차주식회사 | 운전자 보호장치 |
EP2872485B1 (en) | 2012-07-13 | 2020-12-16 | Wave Life Sciences Ltd. | Asymmetric auxiliary group |
RU2015104762A (ru) | 2012-07-13 | 2018-08-31 | Уэйв Лайф Сайенсес Лтд. | Хиральный контроль |
CN104684923B (zh) | 2012-07-13 | 2018-09-28 | 株式会社新日本科学 | 手性核酸佐剂 |
KR20150119924A (ko) * | 2013-02-18 | 2015-10-26 | 스프링 뱅크 파마슈티칼스, 인크. | 백신 애쥬번트 및 치료제로서의 짧은 올리고뉴클레오티드의 설계 |
US10322173B2 (en) | 2014-01-15 | 2019-06-18 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent |
WO2015108048A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
JPWO2015108047A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤 |
PT3094728T (pt) | 2014-01-16 | 2022-05-19 | Wave Life Sciences Ltd | Desenho quiral |
GB201403697D0 (en) * | 2014-03-03 | 2014-04-16 | Link Technologies Ltd | Compounds and methods of use |
EP3197459A4 (en) * | 2014-09-28 | 2018-06-20 | Huahui Health Ltd. | Polymeric bile acid derivatives inhibit hepatitis b and d virus and ntcp transport |
TW201642872A (zh) * | 2015-04-07 | 2016-12-16 | 春季銀行製藥公司 | 用於治療hcv感染之組成物和方法 |
CA2991156A1 (en) * | 2015-07-02 | 2017-01-05 | Spring Bank Pharmaceuticals, Inc. | Compositions and methods for the treatment of viral infection |
EP3426671A4 (en) * | 2016-03-11 | 2019-11-20 | Spring Bank Pharmaceuticals, Inc. | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF INFECTIONS |
AU2017295883A1 (en) * | 2016-07-15 | 2019-02-21 | Sperovie Biosciences, Inc. | Compounds, compositions, and methods for the treatment of disease |
JOP20170192A1 (ar) * | 2016-12-01 | 2019-01-30 | Takeda Pharmaceuticals Co | داي نوكليوتيد حلقي |
US20200055883A1 (en) | 2017-02-17 | 2020-02-20 | Eisai R&D Management Co., Ltd. | Cyclic di-nucleotides derivative for the treatment of cancer |
AR113224A1 (es) | 2017-04-28 | 2020-02-19 | Novartis Ag | Conjugados de anticuerpo que comprenden un agonista de sting |
WO2019051488A1 (en) | 2017-09-11 | 2019-03-14 | Sperovie Biosciences, Inc. | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE |
WO2019051489A1 (en) * | 2017-09-11 | 2019-03-14 | Sperovie Biosciences, Inc. | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE |
CN110467647B (zh) * | 2018-05-09 | 2022-08-30 | 博瑞生物医药(苏州)股份有限公司 | 双核苷酸前体药物的制备方法 |
CN110467646A (zh) * | 2018-05-09 | 2019-11-19 | 博瑞生物医药(苏州)股份有限公司 | 双核苷酸前体药物 |
WO2019219070A1 (zh) * | 2018-05-18 | 2019-11-21 | 正大天晴药业集团股份有限公司 | 氘代的低聚核苷酸及前体药物 |
JP7335277B2 (ja) | 2018-06-01 | 2023-08-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 膀胱がんの治療のための方法 |
FR3082434B1 (fr) | 2018-06-14 | 2021-04-30 | Cairdac | Implant cardiaque autonome de type "capsule leadless", comprenant un recuperateur d'energie a lame piezoelectrique |
AU2019322722A1 (en) | 2018-08-16 | 2020-10-15 | Eisai R&D Management Co., Ltd. | Salts of compounds and crystals thereof |
EP3873938A1 (en) | 2018-10-31 | 2021-09-08 | Novartis AG | Dc-sign antibody conjugates comprising sting agonists |
WO2020089815A1 (en) | 2018-10-31 | 2020-05-07 | Novartis Ag | Antibody conjugates comprising sting agonist |
CN113164506B (zh) * | 2018-12-06 | 2023-12-08 | 正大天晴药业集团股份有限公司 | 二核苷酸化合物及其前体药物 |
CN111484541B (zh) * | 2019-01-25 | 2023-06-02 | 博瑞生物医药(苏州)股份有限公司 | 双核苷酸前体药物及其制备方法 |
CN111484540B (zh) * | 2019-01-25 | 2023-09-08 | 博瑞生物医药(苏州)股份有限公司 | 含双核苷酸结构的化合物 |
JP7421280B2 (ja) | 2019-07-30 | 2024-01-24 | 三和シヤッター工業株式会社 | 建具 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US688183A (en) | 1900-12-17 | 1901-12-03 | Carl C Lantz | Adjusting-clip for garment-supporters. |
DE2817041C2 (de) | 1978-04-19 | 1987-02-19 | Reich Spezialmaschinen GmbH, 7440 Nürtingen | Vorrichtung zum Aufteilen von Platten |
CS264222B1 (en) * | 1986-07-18 | 1989-06-13 | Holy Antonin | N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them |
US5204466A (en) | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
US6642245B1 (en) | 1990-02-01 | 2003-11-04 | Emory University | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
EP0525057B1 (en) | 1990-04-18 | 2000-06-14 | Procter & Gamble Pharmaceuticals, Inc. | Antimicrobial quinolonyl lactams |
US5444063A (en) | 1990-12-05 | 1995-08-22 | Emory University | Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity |
US5432165A (en) | 1992-04-06 | 1995-07-11 | Oclassen Pharmaceuticals, Inc. | Methods for the treatment of infection caused by Hepatitis B virus (HBV) |
FR2705099B1 (fr) | 1993-05-12 | 1995-08-04 | Centre Nat Rech Scient | Oligonucléotides phosphorothioates triesters et procédé de préparation. |
US5955591A (en) | 1993-05-12 | 1999-09-21 | Imbach; Jean-Louis | Phosphotriester oligonucleotides, amidites and method of preparation |
FR2709754B1 (fr) | 1993-09-10 | 1995-12-01 | Centre Nat Rech Scient | Composés 2' ou 3'-déoxy- et 2', 3'-didéoxy-beta-L-pentofuranonucléosides, procédé de préparation et application thérapeutique, notamment anti-virale. |
US5587362A (en) | 1994-01-28 | 1996-12-24 | Univ. Of Ga Research Foundation | L-nucleosides |
US5581639A (en) | 1995-05-04 | 1996-12-03 | National Research Council Of Canada | Raman-nath diffraction grating |
WO1998007734A1 (en) | 1996-08-21 | 1998-02-26 | Hybridon, Inc. | Oligonucleotide prodrugs |
WO1998017281A1 (en) | 1996-10-24 | 1998-04-30 | Vion Pharmaceuticals, Inc. | MONOPHOSPHATE PRODRUGS OF β-L-FD4C AND β-L-FddC AS POTENT ANTIVIRAL AGENTS |
CA2340156C (en) | 1998-08-10 | 2007-10-23 | Novirio Pharmaceuticals Limited | .beta.-l-2'-deoxy-nucleosides for the treatment of hepatitis b |
CA2599597A1 (en) | 1998-08-10 | 2000-02-24 | Idenix (Cayman) Limited | .beta.-l-2'-deoxy-nucleosides for the treatment of hepatitis b |
US6444652B1 (en) | 1998-08-10 | 2002-09-03 | Novirio Pharmaceuticals Limited | β-L-2'-deoxy-nucleosides for the treatment of hepatitis B |
US6875751B2 (en) | 2000-06-15 | 2005-04-05 | Idenix Pharmaceuticals, Inc. | 3′-prodrugs of 2′-deoxy-β-L-nucleosides |
CN1291994C (zh) | 2000-07-21 | 2006-12-27 | 吉里德科学公司 | 核苷酸膦酸酯类似物前药及其筛选和制备方法 |
WO2002092006A2 (en) * | 2001-05-16 | 2002-11-21 | Micrologix Biotech, Inc. | Nucleic acid-based compounds and methods of use thereof |
US8076303B2 (en) * | 2005-12-13 | 2011-12-13 | Spring Bank Pharmaceuticals, Inc. | Nucleotide and oligonucleotide prodrugs |
CN101146337B (zh) | 2006-09-15 | 2011-04-20 | 华为技术有限公司 | 新接入节点随机接入的方法及其系统 |
WO2009146123A2 (en) * | 2008-04-03 | 2009-12-03 | Spring Bank | Compositions and methods for treating viral infections |
-
2006
- 2006-12-12 US US11/637,520 patent/US8076303B2/en not_active Expired - Fee Related
- 2006-12-13 KR KR1020117025810A patent/KR101248873B1/ko active IP Right Grant
- 2006-12-13 WO PCT/US2006/047617 patent/WO2007070598A2/en active Application Filing
- 2006-12-13 PL PL16158945T patent/PL3090748T3/pl unknown
- 2006-12-13 ES ES16158945T patent/ES2729657T3/es active Active
- 2006-12-13 SI SI200632329T patent/SI3090748T1/sl unknown
- 2006-12-13 ES ES06848625.7T patent/ES2573928T3/es active Active
- 2006-12-13 CN CN201210257654.3A patent/CN102796155B/zh not_active Expired - Fee Related
- 2006-12-13 PL PL06848625.7T patent/PL1968612T3/pl unknown
- 2006-12-13 LT LTEP16158945.2T patent/LT3090748T/lt unknown
- 2006-12-13 KR KR1020087015713A patent/KR101123534B1/ko active IP Right Grant
- 2006-12-13 PT PT16158945T patent/PT3090748T/pt unknown
- 2006-12-13 EP EP06848625.7A patent/EP1968612B1/en active Active
- 2006-12-13 CN CN2006800509299A patent/CN101437397B/zh not_active Expired - Fee Related
- 2006-12-13 SI SI200632048A patent/SI1968612T1/sl unknown
- 2006-12-13 IN IN1786DEN2015 patent/IN2015DN01786A/en unknown
- 2006-12-13 HU HUE06848625A patent/HUE029190T2/en unknown
- 2006-12-13 RS RS20160328A patent/RS54867B1/sr unknown
- 2006-12-13 JP JP2008545782A patent/JP5044854B2/ja not_active Expired - Fee Related
- 2006-12-13 EP EP19157583.6A patent/EP3553072A1/en not_active Withdrawn
- 2006-12-13 HU HUE16158945A patent/HUE044034T2/hu unknown
- 2006-12-13 DK DK16158945.2T patent/DK3090748T3/da active
- 2006-12-13 EP EP16158945.2A patent/EP3090748B1/en active Active
- 2006-12-13 DK DK06848625.7T patent/DK1968612T3/en active
-
2011
- 2011-11-14 US US13/296,221 patent/US8691787B2/en not_active Expired - Fee Related
-
2014
- 2014-02-21 US US14/186,768 patent/US20140323554A1/en not_active Abandoned
-
2015
- 2015-11-12 US US14/939,397 patent/US10047114B2/en not_active Expired - Fee Related
-
2016
- 2016-05-09 CY CY20161100388T patent/CY1117576T1/el unknown
- 2016-05-18 HR HRP20160531TT patent/HRP20160531T1/hr unknown
-
2018
- 2018-03-15 US US15/922,581 patent/US10344046B2/en not_active Expired - Fee Related
-
2019
- 2019-05-20 CY CY20191100534T patent/CY1121639T1/el unknown
- 2019-05-23 US US16/420,311 patent/US20200087338A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101123534B1 (ko) | 뉴클레오티드 및 올리고뉴클레오티드 전구약물 | |
US20200147124A1 (en) | S-antigen transport inhibiting oligonucleotide polymers and methods | |
KR101620394B1 (ko) | 바이러스 감염증을 치료하기 위한 조성물 및 방법 | |
US7582748B2 (en) | Methods of manufacture of 2′-deoxy-β-L-nucleosides | |
JPH10505094A (ja) | オリゴヌクレオチドプロドラッグ | |
US11166976B2 (en) | S-antigen transport inhibiting oligonucleotide polymers and methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
J201 | Request for trial against refusal decision | ||
A107 | Divisional application of patent | ||
AMND | Amendment | ||
B701 | Decision to grant | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20150224 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20160211 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20170222 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20180209 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20190220 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20200219 Year of fee payment: 9 |